Astrocytoma, Grade IV Clinical Trial
Official title:
A Phase IB Study to Use Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma
Increasing preclinical and clinical data have shown that myeloid-derived suppressor cells (MDSCs) may represent a significant driver of immunosuppression in glioblastoma (GBM, grade IV astrocytoma) and a potential mechanism of treatment resistance to chemoradiotherapy. Tadalafil, an FDA-approved drug with inexpensive cost and excellent safety profile, has been shown to effectively reduce MDSCs and restore T-cell activation in the peripheral blood and in the tumor microenvironment. The purpose of this study is to investigate the impact of targeting MDSCs in newly diagnosed IDH-wildtype grade III-IV astrocytoma by combining tadalafil with standard of care radiation therapy (RT) and temozolomide (TMZ).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02766699 -
A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM)
|
Phase 1 | |
Not yet recruiting |
NCT06017063 -
Coaching for Coping in Glioblastoma Patients and Caregivers and Its Association With Compliance to TTFields
|
N/A | |
Completed |
NCT02366728 -
DC Migration Study for Newly-Diagnosed GBM
|
Phase 2 | |
Terminated |
NCT04489420 -
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
|
Phase 1 | |
Withdrawn |
NCT02432417 -
The Addition of Chloroquine to Chemoradiation for Glioblastoma,
|
Phase 2 | |
Withdrawn |
NCT05218408 -
CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type
|
Phase 1/Phase 2 | |
Recruiting |
NCT05375318 -
BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels
|
||
Not yet recruiting |
NCT06161974 -
Study of Olutasidenib and Temozolomide in HGG
|
Phase 2 | |
Withdrawn |
NCT00943462 -
Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM
|
||
Completed |
NCT02709226 -
Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
|
Phase 1 | |
Recruiting |
NCT05229198 -
ALBATROSS Study: International Multicenter Study for Prospective Validation of Imaging Biomarkers Calculated at Vascular Habitats of High-grade Gliomas
|
||
Completed |
NCT01240460 -
Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection
|
Phase 1 | |
Recruiting |
NCT06118723 -
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
|
||
Recruiting |
NCT06157541 -
T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 | |
Terminated |
NCT02510950 -
Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
|
Phase 1 | |
Withdrawn |
NCT03956706 -
Study of Stereotactic Radiosurgery to the Subventricular Zone in Malignant Gliomas
|
N/A | |
Completed |
NCT02465268 -
Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT03072134 -
Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
|
Phase 1 | |
Recruiting |
NCT03861299 -
The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients.
|
N/A |